Neuronetics, Inc. Research and Development Expense
Neuronetics, Inc. (STIM) reported Research and Development Expense of $1.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- Neuronetics, Inc. research and development expense for the quarter ending 2026-06-30 was $1.34M, a 25.70% decline year-over-year.
- Neuronetics, Inc. research and development expense for the quarter ending 2026-03-31 was $1.36M, a 15.59% decline year-over-year.
- Neuronetics, Inc. research and development expense for the quarter ending 2025-12-31 was $1.67M, a 71.14% decline year-over-year.
- Neuronetics, Inc. research and development expense for the quarter ending 2025-09-30 was $1.50M, a 37.75% decline year-over-year.
- Neuronetics, Inc. research and development expense for fiscal 2025 was $6.58M, a 48.45% decline from fiscal 2024.
- Neuronetics, Inc. research and development expense for fiscal 2024 was $12.77M, a 34.22% increase from fiscal 2023.
- Neuronetics, Inc. research and development expense for fiscal 2023 was $9.52M, a 1.92% increase from fiscal 2022.
- Neuronetics, Inc. research and development expense for fiscal 2022 was $9.34M, a 17.83% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.34M 10-Q · filed 2026-08-11 | $2.70M 10-Q · filed 2026-08-11 | $4.37M derived: sum of 3 quarters · filed 2026-08-11 | $5.87M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $1.36M 10-Q · filed 2026-05-05 | $3.03M derived: sum of 2 quarters · filed 2026-05-05 | $4.53M derived: sum of 3 quarters · filed 2026-05-05 | $6.33M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-12-31 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $3.17M derived: sum of 2 quarters · filed 2026-03-17 | $4.97M derived: sum of 3 quarters · filed 2026-08-11 | $6.58M 10-K · filed 2026-03-17 | ||
| 2025-09-30 | $1.50M 10-Q · filed 2025-11-04 | $3.30M derived: sum of 2 quarters · filed 2026-08-11 | $4.92M 10-Q · filed 2025-11-04 | $10.69M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-06-30 | $1.80M 10-Q · filed 2026-08-11 | $3.41M 10-Q · filed 2026-08-11 | $9.19M derived: sum of 3 quarters · filed 2026-08-11 | $11.60M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $1.62M 10-Q · filed 2026-05-05 | $7.39M derived: sum of 2 quarters · filed 2026-05-05 | $9.80M derived: sum of 3 quarters · filed 2026-05-05 | $12.04M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2024-12-31 | $5.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $8.19M derived: sum of 2 quarters · filed 2026-03-17 | $10.42M derived: sum of 3 quarters · filed 2026-03-17 | $12.77M 10-K · filed 2026-03-17 | ||
| 2024-09-30 | $2.42M 10-Q · filed 2025-11-04 | $4.65M derived: sum of 2 quarters · filed 2025-11-04 | $7.00M 10-Q · filed 2025-11-04 | $16.16M derived: sum of 4 quarters · filed 2026-03-17 | ||
| 2024-06-30 | $2.23M 10-Q · filed 2025-08-05 | $4.58M 10-Q · filed 2025-08-05 | $13.74M derived: sum of 3 quarters · filed 2026-03-17 | $13.88M derived: sum of 4 quarters · filed 2026-03-17 | ||
| 2024-03-31 | $2.35M 10-Q · filed 2025-05-06 | $11.51M derived: sum of 2 quarters · filed 2026-03-17 | $11.65M derived: sum of 3 quarters · filed 2026-03-17 | $14.01M derived: sum of 4 quarters · filed 2026-03-17 | ||
| 2023-12-31 | $9.16M derived: 10-K 12 month − 8-K/A 9 month · filed 2026-03-17 | $9.30M derived: sum of 2 quarters · filed 2026-03-17 | $11.66M derived: sum of 3 quarters · filed 2026-03-17 | $9.52M 10-K · filed 2026-03-17 | ||
| 2023-09-30 | $137.77K 8-K/A · filed 2025-02-06 | $2.15M 10-Q · filed 2023-11-07 | $2.50M derived: sum of 2 quarters · filed 2025-02-06 | $355.83K 8-K/A · filed 2025-02-06 | $7.31M 10-Q · filed 2023-11-07 | $8.43M derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-06-30 | $2.36M 10-Q · filed 2024-08-12 | $5.15M 10-Q · filed 2024-08-12 | $8.29M derived: sum of 3 quarters · filed 2025-03-27 | $10.64M derived: sum of 4 quarters · filed 2025-03-27 | ||
| 2023-03-31 | $2.79M 10-Q · filed 2024-05-07 | $5.93M derived: sum of 2 quarters · filed 2025-03-27 | $8.28M derived: sum of 3 quarters · filed 2025-03-27 | $10.32M derived: sum of 4 quarters · filed 2025-03-27 | ||
| 2022-12-31 | $3.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $5.49M derived: sum of 2 quarters · filed 2025-03-27 | $7.53M derived: sum of 3 quarters · filed 2025-03-27 | $9.34M 10-K · filed 2025-03-27 | ||
| 2022-09-30 | $2.35M 10-Q · filed 2023-11-07 | $4.39M derived: sum of 2 quarters · filed 2023-11-07 | $6.20M 10-Q · filed 2023-11-07 | $7.94M derived: sum of 4 quarters · filed 2024-03-08 | ||
| 2022-06-30 | $2.04M 10-Q · filed 2023-08-08 | $3.85M 10-Q · filed 2023-08-08 | $5.59M derived: sum of 3 quarters · filed 2024-03-08 | $7.17M derived: sum of 4 quarters · filed 2024-03-08 | ||
| 2022-03-31 | $1.80M 10-Q · filed 2023-05-15 | $3.55M derived: sum of 2 quarters · filed 2024-03-08 | $5.12M derived: sum of 3 quarters · filed 2024-03-08 | $7.42M derived: sum of 4 quarters · filed 2024-03-08 | ||
| 2021-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $3.32M derived: sum of 2 quarters · filed 2024-03-08 | $5.61M derived: sum of 3 quarters · filed 2024-03-08 | $7.92M 10-K · filed 2024-03-08 | ||
| 2021-09-30 | $1.57M 10-Q · filed 2022-11-08 | $3.87M derived: sum of 2 quarters · filed 2022-11-08 | $6.18M 10-Q · filed 2022-11-08 | $8.29M derived: sum of 4 quarters · filed 2022-11-08 | ||
| 2021-06-30 | $2.29M 10-Q · filed 2022-08-02 | $4.60M 10-Q · filed 2022-08-02 | $6.72M derived: sum of 3 quarters · filed 2022-08-02 | $8.67M derived: sum of 4 quarters · filed 2022-08-02 | ||
| 2021-03-31 | $2.31M 10-Q · filed 2022-05-12 | $4.42M derived: sum of 2 quarters · filed 2022-05-12 | $6.38M derived: sum of 3 quarters · filed 2022-05-12 | $8.49M derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $2.11M 10-K · filed 2021-03-02 | $4.06M derived: sum of 2 quarters · filed 2021-11-09 | $6.18M derived: sum of 3 quarters · filed 2021-11-09 | $9.20M 10-K · filed 2023-03-07 | ||
| 2020-09-30 | $1.95M 10-Q · filed 2021-11-09 | $4.07M derived: sum of 2 quarters · filed 2021-11-09 | $7.09M 10-Q · filed 2021-11-09 | $11.34M derived: sum of 4 quarters · filed 2021-11-09 | ||
| 2020-06-30 | $2.12M 10-Q · filed 2021-08-03 | $5.14M 10-Q · filed 2021-08-03 | $9.38M derived: sum of 3 quarters · filed 2021-08-03 | $12.87M derived: sum of 4 quarters · filed 2021-08-03 | ||
| 2020-03-31 | $3.02M 10-Q · filed 2021-05-04 | $7.27M derived: sum of 2 quarters · filed 2021-05-04 | $10.76M derived: sum of 3 quarters · filed 2021-05-04 | $13.98M derived: sum of 4 quarters · filed 2021-05-04 | ||
| 2019-12-31 | $4.25M 10-K · filed 2021-03-02 | $7.74M derived: sum of 2 quarters · filed 2021-03-02 | $10.96M derived: sum of 3 quarters · filed 2021-03-02 | $13.75M 10-K · filed 2022-03-08 | ||
| 2019-09-30 | $3.49M 10-K · filed 2021-03-02 | $6.71M derived: sum of 2 quarters · filed 2021-03-02 | $9.50M 10-Q · filed 2020-11-02 | $11.72M derived: sum of 4 quarters · filed 2021-03-02 | ||
| 2019-06-30 | $3.22M 10-K · filed 2021-03-02 | $6.01M 10-Q · filed 2020-08-04 | $8.23M derived: sum of 3 quarters · filed 2021-03-02 | $10.36M derived: sum of 4 quarters · filed 2021-03-02 | ||
| 2019-03-31 | $2.79M 10-K · filed 2021-03-02 | $5.01M derived: sum of 2 quarters · filed 2021-03-02 | $7.13M derived: sum of 3 quarters · filed 2021-03-02 | $9.46M derived: sum of 4 quarters · filed 2021-03-02 | ||
| 2018-12-31 | $2.22M 10-K · filed 2020-03-03 | $4.35M derived: sum of 2 quarters · filed 2020-03-03 | $6.68M derived: sum of 3 quarters · filed 2020-03-03 | $8.23M 10-K · filed 2021-03-02 | ||
| 2018-09-30 | $2.13M 10-K · filed 2020-03-03 | $4.46M derived: sum of 2 quarters · filed 2020-03-03 | $6.01M 10-Q · filed 2019-11-05 | $7.93M derived: sum of 4 quarters · filed 2020-03-03 | ||
| 2018-06-30 | $2.33M 10-K · filed 2020-03-03 | $3.88M 10-Q · filed 2019-08-06 | $5.80M derived: sum of 3 quarters · filed 2020-03-03 | $7.65M derived: sum of 4 quarters · filed 2020-03-03 | ||
| 2018-03-31 | $1.55M 10-K · filed 2020-03-03 | $3.47M derived: sum of 2 quarters · filed 2020-03-03 | $5.32M derived: sum of 3 quarters · filed 2020-03-03 | $7.46M derived: sum of 4 quarters · filed 2020-03-03 | ||
| 2017-12-31 | $1.92M 10-K · filed 2019-03-05 | $3.76M derived: sum of 2 quarters · filed 2019-03-05 | $5.91M derived: sum of 3 quarters · filed 2019-03-05 | $7.94M 10-K · filed 2020-03-03 | ||
| 2017-09-30 | $1.84M 10-K · filed 2019-03-05 | $3.99M derived: sum of 2 quarters · filed 2019-03-05 | $6.02M 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | $2.15M 10-K · filed 2019-03-05 | $4.17M 10-Q · filed 2018-08-14 | ||||
| 2017-03-31 | $2.03M 10-K · filed 2019-03-05 | |||||
| 2016-12-31 | $8.22M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |